Clinical trials: Albumin
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
- Trial name
- NCT02009332
- Testing
- ABI-009, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aadi Bioscience, Inc.
Acute-On-Chronic Liver Failure
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects.
- Trial name
- APACHE (NCT03702920)
- Testing
- SMT + PE-A 5%, Standard Medical Treatment
- Where
- 30 sites in United States, Austria and 7 more
- Volunteers
- 274 people
- Sponsor
- Instituto Grifols, S.A.
Diabetic Nephropathies
An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
Diabetic kidney disease (nephropathy) develops in nearly 40% of patients with type 2 diabetes mellitus. Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys due to uncontrolled blood sugar levels…
- Trial name
- IDEAL-2 (NCT03216564)
- Testing
- Calcitriol
- Where
- Qatar
- Volunteers
- 320 people
- Sponsor
- Hamad Medical Corporation
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
Dehiscence, Surgical Wound
Evaluation of Safety and Efficacy of Using Seraffix LTB - System for Excisional Biopsy Wounds Closure
The purpose of this study is to evaluate the safety and effectiveness of using Seraffix LTB system for excisional biopsy wounds closure
- Trial name
- NCT00525434
- Testing
- Seraffix LTB
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Seraffix
Chronic Hepatitis C
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination…
- Trial name
- NCT00411385
- Testing
- albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
- Where
- 159 sites in United States, Argentina and 19 more
- Volunteers
- 933 people
- Sponsor
- Human Genome Sciences Inc.
Locally Advanced Pancreatic Cancer
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.
- Trial name
- NCT05653453
- Testing
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel, Gemcitabine hydrochloride and albumin binding paclitaxel
- Where
- 5 sites in China
- Volunteers
- 512 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Pancreatic Cancer
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and…
- Trial name
- NCT04624217
- Testing
- SHR-1701
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease (AD)
Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT06489015
- Testing
- Recombinant Human Serum Albumin
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Protgen Co., Ltd.
Advanced Solid Tumors
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
This is a randomized, open-label, two-period, crossover trial to evaluate the pharmacokinetic profiles of albumin-bound docetaxel for intravenous infusion and Taxotere in patients with advanced solid tumors.
- Trial name
- NCT04811118
- Testing
- Docetaxel for Injection (Albumin-bound), Taxotere
- Where
- China
- Volunteers
- 27 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Volunteers
Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese healthy volunteers.
- Trial name
- NCT01901198
- Testing
- Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C., Peginterferon 180 mcg single dose S.C.
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Beijing Bio-Fortune Ltd.
Advanced Pancreatic Adenocarcinoma
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
The Phase Ib/II study is an open-label, single-arm, multicenter trial designed to assess the efficacy and safety of Y101D in combination with Gemcitabine and Albumin Paclitaxel as first-line systemic treatment for advanced…
- Trial name
- NCT06266143
- Testing
- Y101D
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Squamous Cell Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable…
- Trial name
- NCT02027428
- Testing
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance)
- Where
- 119 sites in United States, Germany and 3 more
- Volunteers
- 427 people
- Sponsor
- Celgene
Cocaine Addiction
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
The primary objective of this study is to assess the efficacy and safety of TV-1380 [Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)] in facilitating abstinence in cocaine-dependent subjects.
- Trial name
- NCT01887366
- Testing
- TV-1380 150 mg, TV-1380 300 mg
- Where
- 19 sites in United States, Spain
- Volunteers
- 208 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bioequivalence
Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
The main purpose of this study is to evaluate the bioequivalence of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (100 mg, test product) and Abraxane® (100 mg, reference product) in breast cancer…
- Trial name
- NCT07096869
- Testing
- Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Abraxane®
- Where
- China
- Volunteers
- 28 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Breast Cancer
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally…
- Trial name
- NCT06642545
- Testing
- Disitamab Vedotin, RC148, Albumin-bound Paclitaxone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients
This is an observational study in which data from people with type 2 diabetes mellitus (T2DM) in Germany who use the medical app "myTherapy" are studied.
- Trial name
- SMART-Finder (NCT05552339)
- Testing
- Finerenone (Kerendia, BAY94-8862), Type 2 DM drugs
- Where
- Germany
- Volunteers
- 348 people
- Sponsor
- Bayer
Hemophilia A
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic parameters.
- Trial name
- NCT00289536
- Testing
- Antihemophilic factor, recombinant, manufactured protein-free
- Where
- 8 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baxalta now part of Shire
Hepatitis B Virus
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.
- Trial name
- NCT03294798
- Testing
- Human Serum Albumin/interferon alpha2b fusion protein, Pegasys
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Tianjin SinoBiotech Ltd.